What are your key takeaways from this study, and how do the results influence your perspective on long-term options for the treatment of atopic dermatitis? In your current practice, where does ...

All of those issues can be signs of perioral dermatitis, a common skin condition that appears as a rash around your mouth, nose, and sometimes near your eyes. Here comes the rough part ...

Its importance however, goes beyond these metabolic processes, with recent studies showing its potential benefits in skin diseases, especially dermatitis. Dermatitis refers to a group of ...

Knowing that we don't specifically have head-to-head data amongst our biologic therapies in the atopic dermatitis realm, I kind of like to let the clinical data do the talking, to help guide us.

Its therapeutic qualities have been well documented. However, 1.2 to 6.6% of patients who are patch-tested for dermatitis are sensitive to propolis. The main allergens are 3-methyl-2-butenyl ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

In one particular study involving three patients with leg ulcers, Dooms-Goossens and Degreef discovered that the patients reacted to petrolatums on their leg ulcers despite having negative patch ...

More information on the KT-621 BroADen trial in AD will be available on www.clinicaltrials.gov. Atopic dermatitis (AD) is the most common form of eczema, a chronic inflammatory disease that causes the ...

Besonderes Merkmal der perioralen Dermatitis Die Papeln entstehen im Bereich der Haarfollikel der sogenannten Vellushaare. Hierbei handelt es sich um feine, kurze, wenig pigmentierte Haare, die bis ...

The atopic dermatitis app will launch first in the UK, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later in 2022. Image Phil Taylor ...

receptor pathway in moderate to severe atopic dermatitis (AD). SM17 uniquely binds to the co-receptor for IL-25, a key alarmin, and blocks downstream signaling - disrupting the inflammatory ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 billion. Under the terms of the ...